American Century Companies Inc. Has $994,000 Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

American Century Companies Inc. lifted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,411 shares of the company’s stock after purchasing an additional 703 shares during the quarter. American Century Companies Inc.’s holdings in CRISPR Therapeutics were worth $994,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Capital International Investors grew its stake in CRISPR Therapeutics by 27.8% in the 1st quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock valued at $534,175,000 after buying an additional 1,702,624 shares during the last quarter. Vanguard Group Inc. grew its stake in CRISPR Therapeutics by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock valued at $111,564,000 after buying an additional 46,148 shares during the last quarter. SR One Capital Management LP acquired a new position in CRISPR Therapeutics in the 1st quarter valued at $71,496,000. Avoro Capital Advisors LLC acquired a new position in CRISPR Therapeutics in the 1st quarter valued at $28,599,000. Finally, Baillie Gifford & Co. grew its stake in CRISPR Therapeutics by 2.4% in the 2nd quarter. Baillie Gifford & Co. now owns 405,425 shares of the company’s stock valued at $21,897,000 after buying an additional 9,510 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Guggenheim reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Stifel Nicolaus decreased their price target on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. Truist Financial decreased their price target on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Rodman & Renshaw initiated coverage on shares of CRISPR Therapeutics in a research report on Friday, August 2nd. They issued a “buy” rating and a $90.00 price target on the stock. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Friday, August 16th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $75.63.

CRISPR Therapeutics Stock Down 0.7 %

NASDAQ:CRSP opened at $46.98 on Tuesday. The firm has a market cap of $3.99 billion, a PE ratio of -17.27 and a beta of 1.68. CRISPR Therapeutics AG has a 12 month low of $37.55 and a 12 month high of $91.10. The company’s 50-day moving average price is $49.28 and its two-hundred day moving average price is $55.76.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The firm had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. During the same quarter last year, the firm earned ($0.98) EPS. The company’s quarterly revenue was down 99.3% compared to the same quarter last year. On average, research analysts expect that CRISPR Therapeutics AG will post -5.6 EPS for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.